Printer Friendly

Relationship of Hyperglycaemia, Hypoglycaemia, and Glucose Variability to Atherosclerotic Disease in Type 2 Diabetes.

1. Introduction

Diabetes is known to be associated with both microvascular and macrovascular disease [1]. Whilst good glycaemic control has been consistently shown to reduce microvascular disease, most intervention studies have failed to document a reduction in macrovascular disease outcomes [2, 3].

One possible explanation for this discrepancy is the detrimental effect of hypoglycaemia. Ostgren and colleagues have recently reported a U-shaped relationship of [HbA.sub.1c] with cardiovascular events, including mortality [4]. A recent meta-analysis has also confirmed that hypoglycaemia is associated with a twofold increased risk of cardiovascular disease in type 2 diabetes [5]. Furthermore, both hyperglycaemia and hypoglycaemia following acute coronary syndrome have been associated with increased mortality [6, 7] The traditional explanations of these observations are the proarrhythmogenic effect of hypoglycaemia as a consequence of catecholamine release and QTc prolongation [8, 9] and the unavailability of an energy substrate to the myocardium during hypoglycaemia leading to an ischaemia equivalent [10]. However, the increased mortality extends beyond the hypoglycaemic episode itself. Although a hypoglycaemic episode is known to predict future ones [11], this is unlikely to be the sole mechanism. Another possible contributory mechanism that has not been well investigated is the possibility that hypoglycaemia may accelerate atherosclerosis, as suggested by some animal studies. For example, Yasunari and colleagues reported that repeated hypoglycaemia worsens injuryprovoked intimal thickening in a male Goto-Kakizaki rat carotid artery [12], whilst Jin and colleagues reported that hypoglycaemia induced monocyte adhesion to rat aortic endothelium [13]. Furthermore, a small study found higher carotid and femoral intima-media thickness in 25 subjects with type 1 diabetes and with repeated hypoglycaemic episodes when compared to 20 subjects with type 1 diabetes but without hypoglycaemia [14]. However, continuous glucose monitoring was not performed, and therefore, hyperglycaemic episodes were not captured. Since the two groups had similar [HbA.sub.1c], it is likely that the hypoglycaemic group also had more hyperglycaemia, which might conceivably have contributed to increased intima-media thickness.

Another possible explanation of the failure of clinical trials to demonstrate a beneficial effect of glycaemic control is that none of them targeted reducing fluctuations in blood glucose. Indeed, many forms of treatment may increase blood glucose fluctuations. Acute fluctuations in blood glucose have been shown to be associated with increased mortality [15]. This may be mediated by endothelial dysfunction, oxidative stress, and endothelial cell apoptosis [16]. Such effects of glucose fluctuations could predispose to both microvascular and macrovascular disease.

The aim of this study was therefore to investigate the independent effects of hyperglycaemia, hypoglycaemia, and glucose variability on microvascular and macrovascular disease in type 2 diabetes. Urinary albumin-creatinine served as a marker of microvascular disease. Ankle-brachial index, carotid intima-media thickness, and documented cardiovascular disease served as markers of macrovascular disease. 72-hour continuous glucose monitoring was used to assess hypoglycaemia, hyperglycaemia, and glucose variability. [HBA.sub.1c] and fructosamine served as additional glycaemic indexes.

2. Methods

The study was cross-sectional in nature; data collection was performed over a one-year period, from April 2015 to April 2016. Patients were randomly selected from the list of outpatients attending the Diabetes Centre, Mater Dei Hospital, Malta, during the year 2014. The inclusion criteria were subjects who were diagnosed with type 2 DM according to World Health Organization criteria within the last ten years and were on stable antiglycaemic treatment. Patients suffering from dementia or mental illnesses with the consequent inability to give an informed consent with regard to participation in the study were excluded from the study. Other exclusion criteria included recent admission to hospital with a diabetes-related complication such as hyperglycaemic hyperosmolar ketoacidosis, liver failure, or kidney failure, as well as any other factors that result in glycaemic fluctuations. The study protocol was approved by the University of Malta Research Ethics Committee. All participants gave written informed consent.

2.1. Clinical and Laboratory Measurements. The presence of history of ischaemic heart disease and of cerebrovascular disease was ascertained by use of a questionnaire and by review of medical notes. Height and weight were measured using a calibrated balance and a stadiometer, with the subjects wearing light clothing and without shoes. Body mass index (BMI) was calculated as weight divided by height squared. Waist circumference was measured to the nearest 0.5 cm in the horizontal plane at the midpoint between the lowest rib and the iliac crest [17]. The waist index was calculated as waist circumference (cm) divided by 94 for men and 80 for women [18] Office blood pressure was measured in the supine position after 5 min of rest.

All subjects underwent routine blood investigations in the fasting state on the day of the clinical examination. No medication was taken on the morning of the examination. Patients who were treated with insulin discontinued injections after 22:00 on the day preceding the examination. Estimated glomerular filtration rate (eGFR) was calculated using the Modified Diet in Renal Disease (MDRD) formula (National Kidney Foundation Calculator for Healthcare Professionals). Haemoglobin A1c (measured using high-performance liquid chromatography) and fructosamine were taken as markers of glycaemic control. Urine albumin was measured by an immunoturbidometric technique (Roche Diagnostics, Mannheim, Germany). Creatinine was measured by a kinetic colorimetric test using the Jaffe reaction (Roche Diagnostics). Albumin-creatinine ratio (ACR) was assessed in all patients as a marker of microvascular disease. Body surface area was provided by the Esaote machine used to perform CIMT by inputting weight and height.

2.2. Continuous Glucose Monitoring. Seventy-two-hour subcutaneous continuous glucose monitoring (CGM) was performed in all study participants on an ambulatory basis using the iPro2 continuous glucose-monitoring system (Medtronic MiniMed, Northridge, CA, USA). Participants were advised to pursue their normal daily living without alterations in their usual diet, exercise, and medications taken. Data from the iPro2 were uploaded online via the CareLink iPro software. The following parameters were extracted for each patient: mean blood glucose (MBG), standard deviation of blood glucose (SD), the highest and lowest blood glucose values, the number of high and low excursions, the area under the curve when the blood glucose was higher than 7.8 mmol/L (AUC > 7.8), the area under the curve when the blood glucose was lower than 3.9 mmol/L (AUC < 3.9), the duration (%) when the blood glucose was higher than 7.8mmol/L, the duration (%) when the blood glucose was lower than 3.9 mmol/L, and the duration (%) when the blood glucose was between 3.9 mmol/L and 7.8 mmol/L.

2.3. Carotid Intima-Media Thickness Measurement. Carotid intima-media thickness (CIMT) was assessed in both common carotid arteries in each participant using the Esaote Quality intima media thickness (QIMT[R]). The common carotid artery was utilised since, according to the Mannheim consensus, it increases the accuracy and reproducibility of the measurements obtained. The Esaote QIMT utilises a radio frequency signal to enable measurement of the CIMT with high spatial resolution. The QIMT tool automatically provides accurate measurements of all the parameters which are independent from both the investigator and device settings. Results were categorised as normal or abnormal using age-specific cut-offs, which have been validated in large worldwide databases [19]. Furthermore, all study participants were screened for the presence of carotid plaques in view that the combination of plaque area and thickness have greater value in predicting CVD compared to the thickness alone [17]. Patients with an increased CIMT as assessed by QIMT and/or presence of carotid plaque were categorised as having an abnormal CIMT.

2.4. Clinical Definitions. eGFR was defined as being low if it was <60 mL/min/1.73 [m.sup.2]. PAD was defined as an ABI of [less than or equal to] 0.9. The mean arterial pressure was the average arterial pressure during a single cardiac cycle and pulse pressure the difference between the systolic and diastolic blood pressure readings. Macrovascular disease was defined as the presence of one or more of the following: history of ischaemic heart disease (IHD) or cerebrovascular accident (CVA), ABI < 0.9, or abnormal CIMT.

2.5. Statistical Analysis. All data were analysed using SPSS version 24.0 for Windows. Results are presented as mean [+ or -] standard deviation (SD) or median (interquartile range (IQR)). Continuous variables were checked for normality of distribution using the Kolmogorov-Smirnov method. Comparisons of continuous variables between two groups were made using independent sample t-test for normally distributed variables. For nonparametric variables, the Mann-Whitney U test was used for comparison of 2 groups. Categorical variables were compared using the [chi square] test. The Pearson test was used to test correlation of normally distributed variables, and the Spearman test was used for comparison of non-normally distributed variables.

Univariate followed by multivariate analyses (logistic regression analyses) were performed to identify independent determinants of both the occurrence of macrovascular disease and abnormal CIMT in the study population. Variables were entered into the regression model if their p value was <0.1 in univariate analysis. Predictors were removed from the model if their p value exceeded 0.05.

With regard to ACR, univariate followed by multivariate analysis was again performed with variables with a p value < 0.1 in univariate analysis being included in the multivariate model; however, a generalised linear model was performed as multivariate analysis in view that ACR exhibited a gamma distribution (a right-skewed distribution). All tests were two-sided, and a p value of <0.05 was considered to be statistically significant.

Sample size was determined so as to have statistical power of 90% to detect a moderate effect size ([f.sup.2] = 0.15) at [alpha] = 0.05.

2.6. Role of Funding Source. The study sponsor had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The authors had full access to the data.

3. Results

3.1. Characteristics of Study Population. The study population comprised 121 T2DM subjects of Caucasian origin. The baseline characteristics are outlined in Table 1, whilst continuous glucose-monitoring data are shown in Table 2. Patients had reasonably well-controlled diabetes with a median [HbA.sub.1c] of 6.8% (45 mmol/mol), a median fasting plasma glucose of 7.08 mmol/L, and a mean blood glucose (MBG) during CGM of 7.9 mmol/L. Hyperglycaemic episodes were more prevalent than hypoglycaemic episodes as shown by the number of high and low excursions, the AUC > 7.8 mmol/L and AUC < 3.9 mmol/L, as well as duration of BG > 7.8 mmol/L, between 3.9 and 7.8 mmol/L, and < 3.9 mmol/L. However, none of the study participants reported hypoglycaemic episodes, indicating that all these episodes were subclinical. There were no patients with missing data.

3.2. Predictors of Macrovascular Disease. Seventy-two subjects exhibited macrovascular disease. Univariate followed by multivariate analysis was performed to identify predictors of macrovascular disease in the study population. The results of univariate analysis are shown in Tables 3-5. In univariate analysis, the following variables had a p value < 0.1 and were thus included in the multivariate model: body surface area (BSA), smoking pack years, HDL cholesterol, triglycerides, ESR, lowest blood glucose (BG) value, AUC for BG < 3.9 mmol/L, and duration of BG < 3.9 mmol/L. In multivariate logistic regression analysis, BSA (OR 18.88 (95% CI 2.20-156.69), p = 0.006) and duration of BG < 3.9 mmol/L (OR 1.12 (95% CI 1.014-1.228), p = 0.024) were shown to be independent predictors of macrovascular disease. The relation between presence of cardiovascular disease and duration of BG < 3.9 mmol/L is shown in Figure 1.

3.3. Predictors of Abnormal Carotid Intima-Media Thickness. In the study population, 64 subjects had abnormal CIMT (composite of increased CIMT and presence of carotid plaque). In univariate analysis, the following variables had a p value < 0.1: age, DM duration, smoking pack years, BSA, white cell count, eGFR, ESR, and duration of BG < 3.9 mmol/L. These variables were consequently included in the multivariate model.

Binary logistic regression analysis revealed that BSA (OR 12.6 (95% CI 1.70-93.54), p = 0.013) and duration of BGM < 3.9mmol/L (OR 1.09 (95% CI 1.003-1.187), p = 0.041) were independent predictors of abnormal CIMT. The relation between abnormal CIMT and duration of BG < 3.9 mmol/L is shown in Figure 1.

3.4. Predictors of Albuminuria. The following had p value < 0.1 in univariate analysis: low eGFR (<60 mL/min/1.73[m.sup.2]), white cell count, HDL cholesterol, triglycerides, uric acid, BMI, WI, MBG, SD, AUC for BG > 7.8 mmol/L, duration of BG > 7.8 mmol/L, duration of BG between 3.9 and 7.8 mmol/L, and highest BG value recorded. Generalised linear regression model revealed AUC for BG > 7.8 mmol/L ([beta] = 15.83, p = 0.005) to be the sole independent predictor of albuminuria.

4. Discussion

The present study found that the duration of blood glucose < 3.9 mmol/L was significantly and independently associated with abnormal CIMT and with the composite of abnormal CIMT, ABI, coronary artery disease, and cerebrovascular disease in subjects with type 2 diabetes. This suggests that hypoglycaemia may predispose to atherosclerosis. These findings are consistent with those of the Diabetes Control and Complications Trial (DCCT), which reported that the rate of severe hypoglycaemic episodes in subjects with type 1 diabetes was associated with increased coronary calcium score in those with a [HbA.sub.1c] below 7.5% (58 mmol/L) [18]. It is, however, possible that severe hypoglycaemia was acting as a marker for increased glucose fluctuations. Since we performed CGM, we can exclude this possibility in our study. Furthermore, whilst the DCCT data showed an association of severe hypoglycaemia with increased coronary calcium score in type 1 diabetes, the present study shows a relationship of mild asymptomatic hypoglycaemia, as detected by CGM, to atherosclerosis in type 2 diabetes.

We did not find significant associations of any of the hyperglycaemic indexes (including [HbA.sub.1c], fructosamine, AUC > 7.8 mmol/L, and duration > 7.8 mmol/L) or of glucose fluctuations (as assessed by standard deviation of blood glucose during CGM) with macrovascular disease. However, duration of blood glucose > 7.8 mmol/L was independently associated with ACR. These observations may be related to the short median duration of diabetes in our patients. Our findings are consistent with clinical trial data which have shown that lowering blood glucose for a few years is effective in reducing microvascular but not macrovascular disease [2, 3]. In the UKPDS, it took 10 years of intensive control and a further 10 years of follow-up to demonstrate a beneficial effect of lowering blood glucose on macrovascular outcomes [20]. Another reason could be the relatively good glycaemic control in our cohort.

Our data suggest that hypoglycaemia may have a more rapid effect in promoting atherosclerosis than mild hyperglycaemia or glucose fluctuations. They may help explain the relationship between hypoglycaemia and adverse cardiovascular outcomes even in the short term and why these deleterious effects extend well beyond the period of hypoglycaemia itself. They may also explain why too aggressive lowering of blood glucose in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was associated with increased mortality [21] and why agents such as sulphonylureas [22, 23]and insulin [24] which are prone to cause hypoglycaemia have also been associated with increased mortality and cardiovascular events by some authors.

Hypoglycaemia can promote atherogenesis in a number of ways. Acute hypoglycaemia has been shown to result in decreased nitric oxide bioavailability, increased oxidative stress [25], platelet activation [26], and release of proinflammatory [27], proatherogenic, and prothrombotic cytokines such as PAI-1, VEGF, vascular adhesion molecules, and interleukin-6 [26, 28]. Many of these effects may extend to beyond the hypoglycaemic period [26]. Furthermore, Fadini and colleagues have recently reported that hypoglycaemia may impair endothelial progenitor cell response [29]. Interestingly, Pena and colleagues have reported that hypoglycaemia, but not glucose variability, is associated with endothelial dysfunction in children with type 1 diabetes [30].

Body surface area was also found to be independently associated with atherosclerotic markers. This is probably related to insulin resistance and/or hyperinsulinaemia.

The patients with macrovascular disease were on average younger than those without macrovascular disease. This could be due to the cross-sectional nature of our study. Macrovascular disease shortens life expectancy resulting in a lower average age of subjects with macrovascular disease compared to subjects without. Furthermore, macrovascular disease was associated with hypoglycaemia, which is also known to decrease survival [21]. Duration of diabetes was similar in both groups, meaning that those with macrovascular disease had younger onset type 2 diabetes, which might be associated with higher mortality [31].

A limitation of our study is that we have no information on antecedent glycaemic indexes. This problem is inherent to the study area as it is not practical or ethical to perform CGM over a number of years and not alter management in order to keep glycaemic parameters stable. However, we tried to reduce the impact of this limitation in a number of ways. Firstly, we only recruited patients with stable control, namely, not needing escalation of treatment. Secondly, we studied patients with short duration of diabetes because such patients are less likely to have variation in their glycaemic parameters over the course of their disease. Thirdly, we performed blind, rather than real-time, CGM so that patients did not alter their behaviour as result of the glucose readings. Additionally, patients were instructed not to change their usual routines. In this way, the CGM data are more likely to be representative of the patients' usual glycaemic profile. Furthermore, many glycaemic indices such as [HbA.sub.1c] [32] and hypoglycaemia [11] have been shown to exhibit significant temporal tracking. Another limitation is that in view of the cross-sectional nature of our study, we cannot prove causal relationships. It is possible that those with macrovascular disease were treated more aggressively, hence causing more hypoglycaemia. However, this would not explain the observed relationship with CIMT, which is a subclinical marker of atherosclerosis.

In conclusion, the study suggests that mild asymptomatic hypoglycaemia in subjects with type 2 diabetes is associated with atherosclerotic disease. This cannot be explained by an association of hypoglycaemia with hyperglycaemia or glucose fluctuations. Hyperglycaemic load, as measured by AUC for BG > 7.8 mmol/L, was associated with microalbuminuria.

https://doi.org/10.1155/2018/7464320

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

The study was presented in abstract form at the EuroPrevent meeting held in Ljubljana, Slovenia, April 19-21, 2017.

Conflicts of Interest

The authors have no conflict of interest to declare.

Acknowledgments

The study was sponsored by the Dean's Funds of the University of Malta Medical School.

References

[1] Emerging Risk Factors Collaboration, N. Sarwar, P. Gao et al., "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies," The Lancet, vol. 375, no. 9733, pp. 2215-2222, 2010.

[2] UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)," The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.

[3] ADVANCE Collaborative Group, A. Patel, S. MacMahon et al., "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes," The New England Journal of Medicine, vol. 358, no. 24, pp. 2560-2572, 2008.

[4] C. J. Ostgren, J. Sundstrom, B. Svennblad, L. Lohm, P. M. Nilsson, and G. Johansson, "Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with type 2 diabetes: a cohort study in primary care," Diabetic Medicine, vol. 30, no. 5, pp. e170-e177, 2013.

[5] A. Goto, O. A. Arah, M. Goto, Y. Terauchi, and M. Noda, "Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis," BMJ, vol. 347, article f4533, 2013.

[6] S. Fava, O. Aquilina, J. Azzopardi, H. A. Muscat, and F. F. Fenech, "The prognostic value of blood glucose in diabetic patients with acute myocardial infarction," Diabetic Medicine, vol. 13, no. 1, pp. 80-83, 1996.

[7] A.-M. Svensson, D. K. McGuire, P. Abrahamsson, and M. Dellborg, "Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events," European Heart Journal, vol. 26, no. 13, pp. 1255-1261, 2005.

[8] E. Tu, S. M. Twigg, and C. Semsarian, "Sudden death in type 1 diabetes: the mystery of the "dead in bed" syndrome," International Journal of Cardiology, vol. 138, no. 1, pp. 91-93, 2010.

[9] C. M. Reno, D. Daphna-Iken, Y. S. Chen, J. Vander-Weele, K. Jethi, and S. J. Fisher, "Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation," Diabetes, vol. 62, no. 10, pp. 3570-3581, 2013.

[10] C. Desouza, H. Salazar, B. Cheong, J. Murgo, and V. Fonseca, "Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring," Diabetes Care, vol. 26, no. 5, pp. 1485-1489, 2003.

[11] S. Sreenan, M. Andersen, B. L. Thorsted, M. L. Wolden, and M. Evans, "Increased risk of severe hypoglycemic events with increasing frequency of non-severe hypoglycemic events in patients with type 1 and type 2 diabetes," Diabetes Therapy, vol. 5, no. 2, pp. 447-458, 2014.

[12] E. Yasunari, T. Mita, Y. Osonoi et al., "Repetitive hypoglycemia increases circulating adrenaline level with resultant worsening of intimal thickening after vascular injury in male Goto-Kakizaki rat carotid artery," Endocrinology, vol. 155, no. 6, pp. 2244-2253, 2014.

[13] W. L. Jin, K. Azuma, T. Mita et al., "Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta," Diabetologia, vol. 54, no. 7, pp. 1921-1929, 2011.

[14] M. Gimenez, R. Gilabert, J. Monteagudo et al., "Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes," Diabetes Care, vol. 34, no. 1, pp. 198-203, 2011.

[15] J. G. Timmons, S. G. Cunningham, C. A. R. Sainsbury, and G. C. Jones, "Inpatient glycemic variability and long-term mortality in hospitalized patients with type 2 diabetes," Journal of Diabetes and its Complications, vol. 31, no. 2, pp. 479-482, 2017.

[16] N. Wu, H. Shen, H. Liu, Y. Wang, Y. Bai, and P. Han, "Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo," Cardiovascular Diabetology, vol. 15, no. 1, p. 109, 2016.

[17] M. F. Piepoli, A. W. Hoes, S. Agewall et al., "2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)," Giornale Italiano Di Cardiologia, vol. 18, no. 7, pp. 547-612, 2017.

[18] E. R. Fahrmann, L. Adkins, C. J. Loader et al., "Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study," Diabetes Research and Clinical Practice, vol. 107, no. 2, pp. 280-289, 2015.

[19] L. Engelen, I. Ferreira, C. D. Stehouwer, P. Boutouyrie, S. Laurent, and Reference Values for Arterial Measurements Collaboration, "Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors," European Heart Journal, vol. 34, no. 30, pp. 2368-2380, 2013.

[20] R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-year follow-up of intensive glucose control in type 2 diabetes," The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.

[21] D. E. Bonds, M. E. Miller, R. M. Bergenstal et al., "The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study," BMJ, vol. 340, article b4909, 2010.

[22] O. J. Phung, E. Schwartzman, R. W. Allen, S. S. Engel, and S. N. Rajpathak, "Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis," Diabetic Medicine, vol. 30, no. 10, pp. 1160-1171, 2013.

[23] C. L. Morgan, J. Mukherjee, S. Jenkins-Jones, S. E. Holden, and C. J. Currie, "Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality," Diabetes, Obesity & Metabolism, vol. 16, no. 10, pp. 977-983, 2014.

[24] S. E. Holden, S. Jenkins-Jones, C. L. Morgan, G. Schernthaner, and C. J. Currie, "Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer," Diabetes, Obesity and Metabolism, vol. 17, no. 4, pp. 350-362, 2015.

[25] J. Wang, A. Alexanian, R. Ying et al., "Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 3, pp. 712-720, 2012.

[26] N. G. Joy, D. B. Tate, L. M. Younk, and S. N. Davis, "Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans," Diabetes, vol. 64, no. 7, pp. 2571-2580, 2015.

[27] L. Razavi Nematollahi, A. E. Kitabchi, F. B. Stentz et al., "Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects," Metabolism, vol. 58, no. 4, pp. 443-448, 2009.

[28] B. Kiec-Wilk, B. Matejko, U. Razny et al., "Hypoglycemic episodes are associated with inflammatory status in patients with type 1 diabetes mellitus," Atherosclerosis, vol. 251, pp. 334-338, 2016.

[29] G. P. Fadini, M. Albiero, S. Vigili de Kreutzenberg, and A. Avogaro, "Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients," Journal of Endocrinological Investigation, vol. 38, no. 7, pp. 733-738, 2015.

[30] A. S. Pena, J. J. Couper, J. Harrington et al., "Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes," Diabetes Technology & Therapeutics, vol. 14, no. 6, pp. 457-462, 2012.

[31] S. Zoungas, M. Woodward, Q. Li et al., "Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes," Diabetologia, vol. 57, no. 12, pp. 2465-2474, 2014.

[32] J. A. Edge, T. James, and B. Shine, "Persistent individual tracking within overall improvement in HbA1c in a UK paediatric diabetes clinic over 15 years," Diabetic Medicine, vol. 27, no. 11, pp. 1284-1288, 2010.

Caroline Jane Magri [ID], (1,2) Dillon Mintoff [ID], (3) Liberato Camilleri [ID], (4) Robert G. Xuereb, (2) Joseph Galea, (5) and Stephen Fava [ID] (5)

(1) Department of Cardiology, Mater Dei Hospital and University of Malta, Msida, Malta

(2) Department of Cardiology, Mater Dei Hospital, Msida, Malta

(3) Mater Dei Hospital, Msida, Malta

(4) Statistics & Operations Research, Faculty of Science, University of Malta, Msida, Malta

(5) Mater Dei Hospital and University of Malta, Msida, Malta

Correspondence should be addressed to Stephen Fava; stephen.fava@um.edu.mt

Received 2 January 2018; Revised 1 June 2018; Accepted 24 June 2018; Published 22 July 2018

Academic Editor: Andrea Flex

Caption: Figure 1: Box-and-whisker plot demonstrating relation of duration of glucose < 3.9 mmol/L (expressed as percentage of the entire 72 hr period) and macrovascular disease and carotid intima-media thickness. * denoting outliers.
Table 1: Baseline demographic and clinical findings of study
population.

Patient characteristics (n = 121)                    Values

Age (years) ([dagger])                             64 (57-68)
Male:female (n (%))                           89 (73.6): 32 (26.4)
Diabetes duration (years) ([dagger])                 3 (2-5)
Smoking (current/ex/                              22 (18.2)/41
nonsmokers) (n (%))                             (33.9)/58 (47.9)
Hypertension (n (%))                                80 (66.1)
Hyperlipidaemia (n (%))                             87 (71.9)
Ischaemic heart disease (n (%))                     15 (12.4)
Peripheral arterial disease (n (%))                  7 (5.8)
Cerebrovascular accident/transient                   3 (2.5)
ischaemic attack (n (%))
Abnormal carotid intima-media                       64 (52.9)
thickness (n (%))
Macrovascular disease (n (%))                       72 (59.5)
Chronic kidney disease (n (%))                       9 (7.4)
On metformin (n (%))                               109 (90.1)
On sulphonylurea (n (%))                            36 (29.8)
On gliptins (n (%))                                  6 (5)
On insulin (n (%))                                   6 (5)
On angiotensin-converting enzyme
inhibitor/on angiotensin receptor                   77 (63.6)
blocker (n (%))
On [beta]-blocker (n (%))                           22 (18.2)
On calcium channel blocker (n (%))                  23 (19)
On diuretic (n (%))                                 33 (23.7)
On aspirin (n (%))                                  38 (31.4)
On statin (n (%))                                   81 (66.9)
On fibrate (n (%))                                   7 (5.8)
On allopurinol (n (%))                               5 (4.1)
Body mass index (kg/[m.sup.2]) ([dagger])      31.22 (27.94-34.53)
Body surface area ([m.sup.2]) *                 1.89 [+ or -] 0.21
Waist index *                                   1.19 [+ or -] 0.14
Pulse rate (bpm) ([dagger])                      68 (61.5-78.5)
Mean systolic pressure (mmHg) *               144.19 [+ or -] 17.82
Mean diastolic pressure (mmHg) *               84.60 [+ or -] 8.76
Pulse pressure (mmHg) *                        61.53 [+ or -] 13.66
Mean arterial pressure (mmHg) ([dagger])          107 (93-113)
White cell count (x[10.sup.9]/L) ([dagger])      7.16 (6.26-8.69)
Haemoglobin (g/dL) ([dagger])                   14.35 (13.33-15.18)
Platelet count (x[10.sup.9]/L) ([dagger])       240.5 (206-284.75)
Red blood cell distribution                      13.1 (12.53-13.7)
width (%) ([dagger])
Mean platelet volume (fL) ([dagger])            10.9 (10.2-11.6)
Estimated glomerular filtration                91.22 [+ or -] 24.61
rate (mL/min/1.73 [m.sup.2]) *
Total cholesterol (mmol/L) ([dagger])           4.12 (3.55-5.15)
HDL cholesterol (mmol/L) ([dagger])             1.24 (1.06-1.51)
LDL cholesterol (mmol/L) ([dagger])             2.19 (1.67-3.19)
Non-HDL cholesterol (mmol/L) ([dagger])          2.8 (2.26-3.82)
Triglycerides (mmol/L) ([dagger])                1.36 (0.97-1.7)
Alkaline phosphatase (mmol/L) ([dagger])          69 (55-83.5)
Alanine transaminase (mmol/L) ([dagger])          23 (18-32.5)
Uric acid ([micro]mol/L) *                    313.05 [+ or -] 79.98
Erythrocyte sedimentation rate                     10.5 (6-18)
(mm 1st hr) ([dagger])
Albumin-creatinine ratio                         7.08 (1-23.34)
(mg/mmol) ([dagger])
Fasting plasma glucose (mmol/L) ([dagger])      7.08 (6.11-8.18)
Fructosamine ([micro]mol/L) ([dagger])            278 (257-303)
Glycated haemoglobin (%) ([dagger])               6.8 (6.3-7.6)

Values are expressed as number (%) of patients, * mean [+ or -] SD, or
([dagger]) median (IQR).

Table 2: Baseline continuous glucose-monitoring findings of study
population.

Patient characteristics (n = 121)        Values

Highest value (mmol/L)              13.2 (11.3-15.5)
Lowest value (mmol/L)                3.95 (2.93-5.1)
Mean blood glucose (mmol/L)         7.35 (6.63-8.65)
Standard deviation (mmol/L)           1.9 (1.5-2.3)
Number of high excursions               8 (5-10)
Number of low excursions                 0 (0-2)
AUC above 7.8 mmol/L                0.63 (0.23-1.43)
AUC below 3.9 mmol/L                   0 (0-0.02)
Duration during 72 hr period        37 (19.25-60.75)
with BG above 7.8 mmol/L (%)
Duration during 72 hr period          60 (37.5-77)
with BG within 3.9-7.8 mmol/L (%)
Duration during 72 hr period             0 (0-4)
with BG below 3.9 mmol/L (%)

Values are expressed as median (IQR). AUC: area under curve.

Table 3: Demographic and clinical findings of subjects with and without
macrovascular disease.

                                           No macrovascular disease
Variable                                           (n = 49)

Age (years) ([dagger])                            66 (62-69)
Male:female (n (%))                          34 (69.4): 15 (30.6)
Diabetes duration (years) ([dagger])               3.5 (2-5)
Smoking (current/ex/nonsmokers) (n (%))   4 (8.1)/19 (38.8)/26 (53.1)
Hypertension (n (%))                              29 (59.18)
Hyperlipidaemia (n (%))                           36 (73.47)
CKD (n (%))                                        2 (4.08)
Metformin (n (%))                                 44 (89.80)
Sulphonylurea (n (%))                             14 (28.57)
Gliptins (n (%))                                   4 (8.16)
Insulin (n (%))                                    1 (2.04)
ACEI/ARB (n (%))                                  29 (59.18)
[beta]-blocker (n (%))                             7 (14.29)
CCB (n (%))                                       11 (22.45)
Diuretic (n (%))                                  14 (28.57)
Aspirin (n (%))                                    9 (18.36)
Statin (n (%))                                    29 (59.18)
Fibrate (n (%))                                    6 (12.24)
Allopurinol (n (%))                                2 (4.08)
BMI (kg/[m.sup.2]) ([dagger])                 31.22 (27.67-33.97)
BSA ([m.sup.2]) *                              1.83 [+ or -] 0.20
Waist index *                                  1.17 [+ or -] 0.15
Pulse rate (bpm) ([dagger])                      65 (61-80.25)
Mean SBP (mmHg) *                               146 [+ or -] 18.28
Mean DBP (mmHg) *                             85.66 [+ or -] 7.34
Pulse pressure (mmHg) *                       62.18 [+ or -] 15.6
MAP (mmHg) ([dagger])                          106 (97.5-112.5)

                                             Macrovascular disease
Variable                                           (n = 72)

Age (years) ([dagger])                           61 (54.25-67)
Male:female (n (%))                          55 (76.4): 17 (23.6)
Diabetes duration (years) ([dagger])                3 (2-4)
Smoking (current/ex/nonsmokers) (n (%))   18 (25.0)/22 (30.6)/32 (44.4)
Hypertension (n (%))                              51 (70.83)
Hyperlipidaemia (n (%))                           51 (70.83)
CKD (n (%))                                        7 (9.72)
Metformin (n (%))                                 65 (90.28)
Sulphonylurea (n (%))                             50 (69.44)
Gliptins (n (%))                                   2 (2.77)
Insulin (n (%))                                    5 (6.94)
ACEI/ARB (n (%))                                  48 (66.67)
[beta]-blocker (n (%))                            15 (20.83)
CCB (n (%))                                       12 (16.67)
Diuretic (n (%))                                  19 (26.39)
Aspirin (n (%))                                   29 (40.28)
Statin (n (%))                                    52 (72.22)
Fibrate (n (%))                                    1 (1.39)
Allopurinol (n (%))                                3 (4.17)
BMI (kg/[m.sup.2]) ([dagger])                 31.31 (27.9-35.19)
BSA ([m.sup.2]) *                             1.93 [+ or -] 0.21
Waist index *                                 1.20 [+ or -] 0.13
Pulse rate (bpm) ([dagger])                       71 (62-78)
Mean SBP (mmHg) *                            142.96 [+ or -] 17.54
Mean DBP (mmHg) *                             83.88 [+ or -] 9.58
Pulse pressure (mmHg) *                      61.07 [+ or -] 12.22
MAP (mmHg) ([dagger])                          90.75 (107.5-113)

Variable                                  p value

Age (years) ([dagger])                      0.001
Male:female (n (%))                         0.41
Diabetes duration (years) ([dagger])        0.23
Smoking (current/ex/nonsmokers) (n (%))     0.06
Hypertension (n (%))                        0.24
Hyperlipidaemia (n (%))                     0.84
CKD (n (%))                                 0.31
Metformin (n (%))                           1.00
Sulphonylurea (n (%))                       0.84
Gliptins (n (%))                            0.22
Insulin (n (%))                             0.40
ACEI/ARB (n (%))                            0.44
[beta]-blocker (n (%))                      0.47
CCB (n (%))                                 0.48
Diuretic (n (%))                            0.84
Aspirin (n (%))                             0.02
Statin (n (%))                              0.17
Fibrate (n (%))                             0.02
Allopurinol (n (%))                         1.00
BMI (kg/[m.sup.2]) ([dagger])               0.35
BSA ([m.sup.2]) *                           0.007
Waist index *                               0.22
Pulse rate (bpm) ([dagger])                 0.84
Mean SBP (mmHg) *                           0.36
Mean DBP (mmHg) *                           0.25
Pulse pressure (mmHg) *                     0.68
MAP (mmHg) ([dagger])                       0.77

Values are expressed as number (%) of patients, * mean [+ or -] SD, or
([dagger]) median (IQR). ACEI: angiotensin-converting enzyme inhibitor;
ARB: angiotensin receptor blocker; BMI: body mass index; BSA: body
surface area; CCB: calcium channel blocker; CKD: chronic kidney
disease; CVD: cardiovascular disease; DM: diabetes mellitus; DBP:
diastolic blood pressure; MAP: mean arterial pressure; SBP: systolic
blood pressure.

Table 4: Laboratory findings of subjects with and without
macrovascular disease.

                                                No macrovascular
Variable                                        disease (n = 49)

White cell count (x[10.sup.9]/L) ([dagger])     7.09 (5.88-7.87)
Haemoglobin (g/dL) ([dagger])                   14.2 (13.3-15.1)
Platelet count (x[10.sup.9]/L) ([dagger])       242 (204.5-283.5)
RDW (%) ([dagger])                               13 (12.5-13.45)
MPV (fL) ([dagger])                            10.95 (10.23-11.5)
eGFR (mL/min/1.72 [m.sup.2]) *                87.76 [+ or -] 22.21
Total cholesterol (mmol/L) ([dagger])           4.14 (3.65-5.25)
HDL cholesterol (mmol/L) ([dagger])              1.32 (1.1-1.58)
LDL cholesterol (mmol/L) ([dagger])              2.3 (1.65-3.36)
Non-HDL cholesterol (mmol/L) ([dagger])         2.74 (2.18-3.86)
Triglycerides (mmol/L) ([dagger])               1.13 (0.91-1.64)
ALP (mmol/L) ([dagger])                            66 (52-93)
ALT (mmol/L) ([dagger])                           22 (17.5-32)
Uric acid ([micro]mol/L) *                    319.56 [+ or -] 83.19
ESR (mm 1st hr) ([dagger])                          13 (7-23)
FPG (mmol/L) ([dagger])                         7.14 (6.02-8.53)
Fructosamine ([micro]mol/L) ([dagger])          281 (259.25-305)
[HbA.sub.1c] (%) ([dagger])                       7.0 (6.3-8.1)
[HbA.sub.1c] (mmol/L) ([dagger])                   53 (45-65)

                                                  Macrovascular
Variable                                        disease (n = 72)

White cell count (x[10.sup.9]/L) ([dagger])     7.29 (6.42-9.24)
Haemoglobin (g/dL) ([dagger])                   14.4 (13.6-15.2)
Platelet count (x[10.sup.9]/L) ([dagger])         239 (206-287)
RDW (%) ([dagger])                              13.1 (12.6-13.8)
MPV (fL) ([dagger])                             10.9 (10.1-11.6)
eGFR (mL/min/1.72 [m.sup.2]) *                 93.58 [+ or -] 26.0
Total cholesterol (mmol/L) ([dagger])            4.1 (3.53-5.11)
HDL cholesterol (mmol/L) ([dagger])             1.24 (1.04-1.46)
LDL cholesterol (mmol/L) ([dagger])              2.18 (1.7-3.13)
Non-HDL cholesterol (mmol/L) ([dagger])         2.83 (2.29-3.78)
Triglycerides (mmol/L) ([dagger])               1.47 (1.14-1.85)
ALP (mmol/L) ([dagger])                           69 (59.25-80)
ALT (mmol/L) ([dagger])                           24 (18-32.75)
Uric acid ([micro]mol/L) *                    308.65 [+ or -] 78.03
ESR (mm 1st hr) ([dagger])                          9 (5-17)
FPG (mmol/L) ([dagger])                         7.08 (6.23-8.05)
Fructosamine ([micro]mol/L) ([dagger])           277 (256-303.5)
[HbA.sub.1c] (%) ([dagger])                       6.7 (6.3-7.4)
[HbA.sub.1c] (mmol/L) ([dagger])                   50 (45-57)

Variable                                      p value

White cell count (x[10.sup.9]/L) ([dagger])    0.13
Haemoglobin (g/dL) ([dagger])                  0.48
Platelet count (x[10.sup.9]/L) ([dagger])      0.78
RDW (%) ([dagger])                             0.13
MPV (fL) ([dagger])                            0.53
eGFR (mL/min/1.72 [m.sup.2]) *                 0.19
Total cholesterol (mmol/L) ([dagger])          0.80
HDL cholesterol (mmol/L) ([dagger])            0.07
LDL cholesterol (mmol/L) ([dagger])            0.81
Non-HDL cholesterol (mmol/L) ([dagger])        0.67
Triglycerides (mmol/L) ([dagger])              0.03
ALP (mmol/L) ([dagger])                        0.89
ALT (mmol/L) ([dagger])                         0.6
Uric acid ([micro]mol/L) *                     0.47
ESR (mm 1st hr) ([dagger])                     0.08
FPG (mmol/L) ([dagger])                        0.55
Fructosamine ([micro]mol/L) ([dagger])         0.77
[HbA.sub.1c] (%) ([dagger])                    0.23
[HbA.sub.1c] (mmol/L) ([dagger])               0.23

Values are expressed as * mean [+ or -] SD or ([dagger]) median (IQR).
Abbreviations: ALP: alkaline phosphatase; ALT: alanine transaminase;
eGFR: estimated glomerular filtration rate; ESR: erythrocyte
sedimentation rate; FPG: fasting plasma glucose; HbAu: glycated
haemoglobin; MPV: mean platelet volume; RDW: red blood cell
distribution width.

Table 5: Continuous glucose-monitoring findings of subjects with
and without macrovascular disease.

                                         No macrovascular
                                              disease
Variable                                     (n = 49)

Highest value (mmol/L) ([dagger])        13.4 (11.3-15.85)
Lowest value (mmol/L) ([dagger])          4.4 (3.2-5.25)
Mean blood glucose (mmol/L) ([dagger])    7.6 (6.85-9.0)
Standard deviation (mmol/L) ([dagger])     3.0 (1.3-2.3)
Number of high excursions ([dagger])         8 (6-10)
Number of low excursions ([dagger])           0 (0-2)
AUC above 7.8 mmol/L ([dagger])          0.64 (0.24-1.76)
AUC below 3.9 mmol/L ([dagger])             0 (0-0.01)
Duration during 72 hr period with BG      37 (18.5-66.5)
above 7.8 mmol/L (%) ([dagger])
Duration during 72 hr period with BG       58 (31.5-79)
within 3.9-7.8 mmol/L (%) ([dagger])
Duration during 72 hr period with BG          0 (0-1)
below 3.9 mmol/L (%) ([dagger])

                                           Macrovascular
                                              disease
Variable                                     (n = 72)        p value

Highest value (mmol/L) ([dagger])         13.0 (11.3-15)      0.35
Lowest value (mmol/L) ([dagger])            3.7 (2.8-5)       0.09
Mean blood glucose (mmol/L) ([dagger])     7.3 (6.6-8.4)       0.3
Standard deviation (mmol/L) ([dagger])     1.8 (1.5-2.4)       0.9
Number of high excursions ([dagger])         8 (5-10)         0.49
Number of low excursions ([dagger])           1 (0-2)         0.10
AUC above 7.8 mmol/L ([dagger])          0.57 (0.21-1.35)     0.39
AUC below 3.9 mmol/L ([dagger])             0 (0-0.03)        0.05
Duration during 72 hr period with BG        35 (20-58)        0.39
above 7.8 mmol/L (%) ([dagger])
Duration during 72 hr period with BG        60 (41-77)        0.63
within 3.9-7.8 mmol/L (%) ([dagger])
Duration during 72 hr period with BG          1 (0-5)         0.02
below 3.9 mmol/L (%) ([dagger])

Values are expressed as number (%) of patients or ([dagger]) median
(IQR). AUC: area under curve.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Magri, Caroline Jane; Mintoff, Dillon; Camilleri, Liberato; Xuereb, Robert G.; Galea, Joseph; Fava,
Publication:Journal of Diabetes Research
Date:Jan 1, 2018
Words:6571
Previous Article:Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus.
Next Article:HbA1c Cutoff Point of 5.9% Better Identifies High Risk of Progression to Diabetes among Chinese Adults: Results from a Retrospective Cohort Study.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |